Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.

Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company announced it was adding two new weight-loss medications to its platform.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

The Food and Drug Administration wants bulk production of the copycats to stop—starting Wednesday for pharmacy-prepared versions of Zepbound ... But telehealth companies and pharmacies that ...

Hims & Hers Health Inc.’s shares rose Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

EDT Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reportsDon't Miss Our End of Quarter Offers: Discover the ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

and Zepbound (tirzepatide) are no longer in shortage. That means consumers who've used compounded weight-loss drugs via telehealth providers will soon need to switch to brand name drugs or pursue ...